Background {#Sec1}
==========

According to the 2019 United Nations Programme on AIDS (UNAIDS) report, around 37.9 million people globally were living with HIV in 2018. In the same year, about 1.7 million people were newly infected and 700, 000 people died from AIDS-related illnesses globally \[[@CR1]\]. Cryptococcosis is one of the most important opportunistic infections among people living with advanced AIDS having defective cellular immune component and is a major contributor to AIDS-related mortality worldwide \[[@CR2]\]. In spite of the increasing availability of antiretroviral treatment (ART), cryptococcal disease continues to be a leading cause of death among HIV infected patients in the developing world \[[@CR3]--[@CR5]\]. Considerable number of HIV-infected population still presents late to care with advanced AIDS \[[@CR6], [@CR7]\].

The burden of the disease is greatest in middle and low-income countries where there is a high prevalence HIV infection \[[@CR8]--[@CR13]\]. Patients taking immunosuppressive drugs and some immunocompetent hosts are also at risk \[[@CR14]\]. Although the infection begins in the lungs, certainly the most common presentation of cryptococcal disease is cryptococcal meningitis (C M) which accounts for 15--20% of all AIDS-related deaths globally, three quarter of which are in sub-Saharan Africa. Coupled with loose adherence to ART and retention in HIV care, an estimated 223, 100 cases of CM resulted in 181, 100 deaths among people living with HIV in 2014 \[[@CR2], [@CR4], [@CR7], [@CR13], [@CR15]\]. Screening patients for subclinical cryptococcal infection at the time of entry into ART programs using point-of-care tools like, cryptococcal antigen (CrAg) immunoassays is highly effective in identifying patients at risk of developing CM, allowing these patients to then be targeted with pre-emptive antifungal therapy to prevent the development of severe disease and mortality \[[@CR16]\].

Cryptococcal infection is primarily caused by *Cryptococcus neoformans* and *C. gattii* species \[[@CR8], [@CR9]\]. *C. neoformans* is encapsulated yeast that can be found in pigeon droppings which causes mild to severe infections like meningitis or disseminated disease in individuals with impaired immunity \[[@CR10]\]. The yeast demonstrates several well-characterized virulence factors that contribute to the success of infection. To mention the common one; tolerance to mammalian body temperature at 37 °C, owning a polysaccharide capsule that protects the yeast from phagocytosis, and a thick cell wall with the deposition of phenolic melanin, which has been proposed to protect the yeast from oxidation \[[@CR11], [@CR12]\].

While the gold standard for diagnosis of cryptococcal disease is culture from bodily fluids, CrAg test is used to presumptively diagnose the disease with sensitivity and specificity close to 100%. There are several methods to detect cryptococcal antigen in CSF or plasma/serum: latex agglutination (LA), enzyme immunoassay (EIA), and lateral flow assay (LFA) \[[@CR6]\]. Recent advances in point-of-care testing, like CrAg test, has made screening and diagnosis of CM rapid, practical, and affordable and have been improving long-term survival. Targeted screening and pre-emptive treatment programs for CrAg are a cost effective method for reducing early mortality \[[@CR17]\].

Some of the independent predictors of positive serum cryptococcal antigenemia includes; CD4(+) T cell counts of ≤100 cells/mm, low body mass index, presenting with neck pain, signs of meningeal irritation, and a recent diagnosis of HIV infection \[[@CR18]--[@CR21]\]. Routine screening of such category of patients may detect cryptococcosis, and hence provide an opportunity for early intervention.

Despite the high burden of cryptococcal meningitis related morbidity and mortality in resource limited settings, reviewed data on prevalence of cryptococcal antigenemia and its predictors is missing \[[@CR22], [@CR23]\]. Hence, data is required on this field to inform policy makers for input to tailor intervention measures. Therefore, this systematic review was conducted to describe the the level of cryptococcal antigenemia and its predictors in resource limited settings.

Methods {#Sec2}
=======

Protocol registration {#Sec3}
---------------------

In accordance with the PRISMA guidelines, this systematic review protocol was registered by the International Prospective Register of Systematic Reviews (PROSPERO) on 01 Feb 2019 with a registration number 'CRD42019119970'.

Eligibly criteria {#Sec4}
-----------------

Studies were selected according to the following criteria; *Study design*: observational quantitative studies, like cross-sectional and cohort studies that reported the prevalence of cryptococcal antigenemia and its predictors. *Participants*: We included studies that employed HIV infected people irrespective of gender and the age group who were tested for cryptococcal antigenemia. *Interventions*: our interests were 1) the level of cryptococcal antigenemia, which was defined as the presence of cryptococcal Ag (CrAg) in the blood (serum or plasma) and 2) its predictors, which are to mean factors that are statistically associated with the positive cryptococcal Ag test in the blood. *Setting*: we included studies with the outcome of interest reported in resource-limited settings (countries, listed as low and middle income economic status based on the 2018/19 World Bank report) \[[@CR24]\]. *Language and publication*: We considered peer-reviewed journal articles, governmental documents and unpublished articles (thesis) reported in English language irrespective of the year of publication.

Information sources and search strategy {#Sec5}
---------------------------------------

This review was done following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols (PRISMA) Guidelines \[[@CR25]\]. Research papers were systematically searched in PubMed/Medline and SCOPUS, the last search was conducted on 22th of Dec, 2018. Manual search from Google scholar and Google databases was also done for grey literature. The search terms were developed in line with the Medical Subject Headings (MeSH) thesaurus using a combination of the big ideas (or 'key terms') which derived from the research question. The reference lists of retrieved articles were probed (forward and back ward searching) to identify articles that were not retrieved from databases and our manual search. The first two authors; AD and DM searched the articles independently.

The domains of the search terms were *Cryptococcus*, cryptococcal antigenemia, cryptococcal meningitis, cryptococcosis*,* cryptococcal antigen/CrAg, associated factors/risk factors (or predictors), HIV, AIDS and resource-limited setting/countries. We combined cryptococcal antigenemia, cryptococcal meningitis*,* cryptococcosis with the Boolean operator "OR", and the result was combined with the other terms with "AND". Full search strategy for the two databases is presented in Supplement 1.

Study selection {#Sec6}
---------------

Research papers that reported the level of cryptococcal antigenemia and its epidemiological predictors in the stated settings were included. Searched articles were directly imported and handled using EndNote X5 citation manager (Thomson Reuters, New York, USA). Based on the PRISMA protocol, duplicated articles were excluded and the titles and abstracts of the remaining papers were screened independently for inclusion in full text evaluation by the first two authors. Differences between the reviewers were resolved through discussion. In case of disagreements the decision was determined by the last author.

Data collection process and data items {#Sec7}
--------------------------------------

Data such as the name of the first author, data collection period and year of publication, country where the study was conducted, mean/median age of the study participants, proportion of male participants, type of the study design, the total number of the study participants, the type of specimen (serum/plasma) used for the CrAg test, the proportion of cryptococcal Ag test result, reported statistically significant predictors for CrAg positive test were extracted from the included articles.

Quality appraisal {#Sec8}
-----------------

To assess the risk of bias, the two authors independently used the nine items (each score one point) based on the Joanna Briggs Institute (JBI) Critical Appraisal tools \[[@CR26]\] for prevalence studies. We assumed that papers that scored \> 50% (i.e [\>]{.ul} 5 of 9 scores) of the weighted value of the tool considered as good quality.

Data synthesis {#Sec9}
--------------

The data extracted from the included studies were fed into a Microsoft Excel and were presented in terms of 1) the proportion of cryptococcal antigenemia from each study; 2) meta-analysis was done using STATA 14.0 to determine the pooled prevalence of cryptococcal antigenemia. A systematic narrative synthesis was provided in which summary results were presented using text, table and figures. Descriptive statistics, such as: simple counts, ranges and percentages were used to describe the synthesized data.

Results {#Sec10}
=======

Search results {#Sec11}
--------------

From the systematically searched databases and other sources, a total of 2941 articles were retrieved and sequentially screened. After removing the duplicate, 2930 were screened by title then 2865 were removed. Consequently, 36 were removed by abstract and 7 by full text with justifiable reasons. Lastly, a total of 22 studies met our inclusion criteria and included in this review for analysis.

Screening was based on the PRISMA flow chart which was adapted from the PRISMA guidelines \[[@CR27]\] (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1The PRISMA flow diagram of literature selection

Study characteristics {#Sec12}
---------------------

The description of each study is presented in (Table [1](#Tab1){ref-type="table"}). The studies were reported in the last decade (2007--2018) in ten different countries. Except three studies that reported in Brazil, Indonesia and Cambodia, \[[@CR28], [@CR29], [@CR45]\] the rest were conducted in Africa. All the included articles were published in peer-reviewed journals. About 19 (86.4%) of the articles used cross-sectional study design; while the remaining three papers were cohort type. The primary interest of most the included papers were to determine the prevalence of cryptococcal antigenemia among HIV infected patients using rapid CrAg test kits. Table 1Characteristics of the included studies*Author (s)\*Pub. YearCountryStudy periodStudy designSample sizeGender, male (%)Median/*\
*Mean/ age*Vidal et al. \[[@CR28]\]2016Brazil2014--15\*CS1636138.3Ganiem et al. \[[@CR29]\]2014Indonesia2014CS81076.330Cheryl et al. \[[@CR30]\]2007Uganda2003--7CS37729.438Beyene et al. \[[@CR31]\]2013Ethiopia2011--12CS25445.333Meya et al. \[[@CR32]\]2010Uganda2004--6CS60931no dataRugemalila et al. \[[@CR33]\]2013Tanzania2011--12CS2184339Longley et al. \[[@CR34]\]2016S. Africa2011--14Cohort6454736Hailu et al. \[[@CR35]\]2017Ethiopia2016--7CS2674938Letang et al. \[[@CR36]\]2015Tanzania2008--12Cohort7504038Christopher et al. \[[@CR37]\]2015Nigeria2010--11CS33346.833Williams et al. \[[@CR38]\]2015Uganda2013--14CS20760.336Alemu et al. \[[@CR39]\]2013Ethiopia2011CS3694436Derbie et al. \[[@CR40]\]2018Ethiopia2016CS13745.332Mamuye et al. \[[@CR41]\]2016Ethiopia2013--14CS1985336.7Oyella et al. \[[@CR42]\]2012Uganda2009--10CS3674832Ogouyemi et al. \[[@CR18]\]2016Benin2015CS35542.340Drain et al. \[[@CR43]\]2015S. Africa2011--13CS4326036.1Mdodo et al. \[[@CR44]\]2010Kenya2008--9CS34047.535Micol et al. \[[@CR45]\]2007Cambodia2004CS3275535Jarvis et al. \[[@CR46]\]2009South Africa2002--5CS7072533.5Wajanga et al. \[[@CR47]\]2011Tanzania2009--10Cohort33346.238.5Magambo et al. \[[@CR48]\]2014Tanzania2012--13CS14042.136\*Pub.year: Publication year \*CS: Cross-sectional study design

In this review, data of 8338 HIV positive individuals (male gender 25--76.3% and median age range 30--40 years) were included.

Risk of bias {#Sec13}
------------

The nine domain-based JBI Critical appraisal tool \[[@CR26]\] for prevalence studies was used to test outcome level risk of bias of each studies. Each domain had a score of 1 point. The risk of bias for each individual domain was measured as 'yes', 'no', 'unclear' and 'not applicable'. In this study, 'yes' scored 1 and 'no' 'unclear' and 'not applicable' scores zero. The score therefore ranges from zero to nine, with higher scores indicating higher quality of outcome. Based on our assumption the overall score ranged 5--7 (i.e all the included articles scored above 50% positive score). Hence, we considered all as good quality articles.

Prevalence of cryptococcal antigenemia {#Sec14}
--------------------------------------

The reported median CD4 count was between 20 and 123cell/. Except a study \[[@CR39]\] that reported mean CD4 count at 123 cells/μl, the rest reported the mean CD4 count \< 100 cells. With regard to ART status of the participants, twelve studies \[[@CR18], [@CR29], [@CR30], [@CR32], [@CR34], [@CR36], [@CR42], [@CR43], [@CR45]--[@CR48]\] included patients who were ART naïve. In contrast, two studies \[[@CR37], [@CR40]\] included participants who were on ART. The remaining articles reported different proportion of ART status of the participants. In addition, the reported proportion of headache (ranged between 10 and 80.6%) and WHO clinical stage IV AIDS (ranged between 17.9 and 100%) by the included articles is depicted in Table [2](#Tab2){ref-type="table"}. Table 2The prevalence of cryptococcal antigemia and distribution of other clinical features of the study participants, 2007--2018*Author (s)Median CD4 count* (cells/μl)*ART statusWHO stage IV* (%)*Had headache (%)*+ *CrAg* test*, n (%)*Vidal et al. \[[@CR28]\]2574% on ART66No data5 (3.1)Ganiem et al. \[[@CR29]\]20All naïveno dataNo data58 (7.1)Cheryl et al. \[[@CR30]\]50All naïve36.2No data22 (5.8)Beyene et al. \[[@CR31]\]-\*47.6% on ATR36.245.726 (10.2)Meya et al. \[[@CR32]\]79All naïveNo data45.750 (8.2)Rugemalila et al. \[[@CR33]\]9644% on ARTNo data667 (3)Longley et al. \[[@CR34]\]55.5All naïveNo dataNo data28 (4.3)Hailu et al. \[[@CR35]\]-\*\*52% on ART45339 (3.4)Letang et al. \[[@CR36]\]71All naïveNo dataNo data28 (3.7)Christopher et al. \[[@CR37]\]-\*\*\*All on ARTNo dataNo data33 (9.9)Williams et al. \[[@CR38]\]2551% on ARTNo dataNo data149 (72)^\^^Alemu et al. \[[@CR39]\]12374% on ART1002831 (8.4)Derbie et al. \[[@CR40]\]51.8All on ARTNo dataNo data16 (11.7)Mamuye et al. \[[@CR41]\]9351% on ART36%3918 (9.1)Oyella et al. \[[@CR42]\]23All naïveNo data37.169 (19)Ogouyemi et al. \[[@CR18]\]-\*\*All naïveNo dataNo data6 (1.7)Drain et al. \[[@CR43]\]75All naïveNo dataNo data39 (9)Mdodo et al. \[[@CR44]\]7230.6% on ARTNo data80.6111 (33)Micol et al. \[[@CR45]\]24All naïve28%52.559 (18)Jarvis et al. \[[@CR46]\]97All naïveNo dataNo data46 (7)Wajanga et al. \[[@CR47]\]68All naïve17.9%No data17 (5.1)Magambo et al. \[[@CR48]\]97All naïve661010 (7.1)Four studies didn't report the exact median CD4 count of their study participants. However, \*about 59 (23.2%) of this particular study participants had CD4 \< 100; \*\*All the study participants of this study had CD4 count \< 100; \*\*\* About 121(36.3%) of this study participants had CD4 \< 200^\^^**Outlier**: subjects were HIV patients suspected for meningitis who were admitted to a hospital. The figure is excluded from the pooled prevalence analysis

The overall reported prevalence of cryptococcal antigenemia was between 1.7 and 33%. Running meta-analysis, the pooled prevalence was at 8% (95%CI: 6--10%) (Table [2](#Tab2){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}). Our sub-group analysis also showed that the prevalence of cryptococcal antigenemia in Ethiopia varied between 3.4 and 11.7%. The pooled prevalence was at 7% (95%CI: 3--11%) among HIV infected patients at different ART status and CD4 count. Fig. 2The pooled prevalence of cryptococcal antigenemia in resource limited settings, 2007--2018

Predictors of cryptococcal antigenemia {#Sec15}
--------------------------------------

The statistically significant predictors of positive cryptococcal antigen test are depicted below in (Table [3](#Tab3){ref-type="table"}). Body mass index\< 18.5 kg/m2, CD4 count \< 100 cells and male gender were reported by two or more articles as an important predictors of cryptococcal antigenemia. Table 3Reported factors associated with cryptococcal antigenemia among HIV infected patients in resource limited settings, 2007--2018*Author (s)Reported predictors for positive CrAg test*Vidal et al. \[[@CR28]\]No dataGaniem et al. \[[@CR29]\]No dataCheryl et al. \[[@CR30]\]No dataBeyene et al. \[[@CR31]\]Being ART naive and ART-defaulterMeya et al. \[[@CR32]\]A cryptococcal diagnosis during follow-upRugemalila et al. \[[@CR33]\]No dataLongley et al. \[[@CR34]\]No dataHailu et al. \[[@CR35]\]Being male, living in rural areas, being hospitalizedLetang et al. \[[@CR36]\]No dataChristopher et al. \[[@CR37]\]Female gender, CD4 count of \< 200 cell/μLWilliams et al. \[[@CR38]\]No dataAlemu et al. \[[@CR39]\]An increasing age, self-reported fever, CD4 count \< 100 cells and site of screening.Derbie et al. \[[@CR40]\]GenderMamuye et al. \[[@CR41]\]Lower median CD4, history of cryptococcal disease, having symptoms of headache, head stiffnessOyella et al. \[[@CR42]\]Low body mass index, CD4+ count of less than 50 cells/mm3, recent diagnosis of HIV infection and meningeal signsOgouyemi et al. \[[@CR18]\]Body mass index\< 18.5 kg/m2, an alteration of the general condition with a CD4 lymphocyte counts\< 50cells/μLDrain et al. \[[@CR43]\]CD4 counts \< 50 cells/μLMdodo et al. \[[@CR44]\]male sex, headache, blurred vision and previous antifungal drug useMicol et al. \[[@CR45]\]Countryside residence, headache, body mass index \< 15.4 kg/m2, CD4+ count \< 50 cells/mm3, male genderJarvis et al. \[[@CR46]\]Baseline CD4 cell count, incident cryptococcal meningitis, history of cryptococcal diseaseWajanga et al. \[[@CR47]\]CD4 counts of \< 100 cells, altered mental status, neck stiffness, feverMagambo et al. \[[@CR48]\]Age, body mass index, CD4 count and WHO stage

Discussion {#Sec16}
==========

Cryptococcal meningitis, a deadly opportunistic fungal infection, is a leading cause of death among people with advanced HIV in resource limited settings \[[@CR15], [@CR49], [@CR50]\]. However, it is one of the neglected topics by public health authorities while most deaths from the diseases are avoidable \[[@CR23], [@CR50]--[@CR53]\]. There is quite few data regarding the prevalence of cryptococcosis in resource limited settings for public health measures. Therefore, in this systematic review data of some 8338 HIV positive individuals is described to uncover the prevalence of cryptococcal antigenemia and its possible predictors. The median age of the patients in the included studies range 30--40 years which implies that HIV infection continue affecting the productive segment of the population.

In this review the reported median CD4 count of the HIV patients was between 20 and 123cell/μl. Except a study \[[@CR39]\], the rest reported mean CD4 count of the participants below 100 cells (range 23--97 cells/μl). On top of this twelve studies \[[@CR18], [@CR29], [@CR30], [@CR32], [@CR34], [@CR36], [@CR42], [@CR43], [@CR45]--[@CR48]\] reported that all the participants were ART naïve. Consequently, low CD4 count coupled with not starting ART would expose HIV infected patients for higher risk of different opportunistic infections including, cryptococcosis.

Our review result showed the overall prevalence of cryptococcal antigenemia between 1.7 and 33%; the pooled prevalence was at 8% (95%CI: 6--10%). A review by Firacative et al. (2018) on the status of cryptococcosis in Latin America reported prevalence of 10--21% \[[@CR22]\] in the context of HIV patients with CM. Although the papers included in the present review recruited patients with different clinical ground, including their different CM status, our finding is still in line with the above report. Similarly, based on Rajasingham et al. (2017) review report on the Global burden of HIV-associated cryptococcal meningitis, the estimated global cryptococcal antigenaemia was at 6% (95%CI 5.8--6.2%) among people with a CD4 cell count of less than 100 cells per μL in 2014. This finding is in line with our pooled estimate at (8%). In addition, according to this report, the Sub-Saharan Africa accounted for 73% of the estimated cryptococcal meningitis cases in 2014. Moreover, the report also highlighted that there might be an ongoing burden of HIV-associated cryptococcal disease, primarily in sub-Saharan Africa \[[@CR54]\]. Ford and his colleague (2018) on their review article reported the global pooled prevalence of cryptococcal antigenemia at 6.5% among HIV patients with CD4 count ≤100 cells/μL which is still comparable with our report \[[@CR55]\].

Another review by Park et al. (2009) aimed at estimating the current global burden of cryptococcal meningitis among persons living with HIV showed an incidence ranged from 0.04 to 12% per year. Sub-Saharan Africa had the highest yearly burden estimate (median incidence at 3.2%). In contrast, the median incidence was lowest in Western and Central Europe and Oceania (\</=0.1% each) \[[@CR5]\]. This implies that the overall prevalence of the disease would be much higher, may be close to or greater than our pooled report at (8%), in poor settings. In contrast, the prevalence of cryptococcosis in the developed world has decreased as there is quite low burden of HIV and is also being diagnosed earlier, but is still significant, and the problem in resource-limited settings is exceedingly high \[[@CR56]\] in which over half of patients die within 10 weeks of diagnosis compared to as few as 10% of patients from developed nations \[[@CR57]\].

The pooled prevalence of cryptococcal antigenemia in Ethiopia was at 7% (95%CI: 3--11%) among HIV infected patients at different clinical context. Comparable reports have been released in Ethiopia and overseas; Bite et al. (2016) had reported (8.5%) positive cryptococcal antigenemia proportion in Addis Ababa, Ethiopia \[[@CR58]\]. Thomsen et al. (2018) reported that, of HIV patients included in a study in Guinea-Bissau, (10%) had a positive cryptococcal antigen test \[[@CR59]\]. On top of this, in our review the pooled prevalence of cryptococcal antigenemia was 11% (Uganda), 4% (Tanzania) and 7% (South Africa). As the HIV patients had different CD4 count, ART status and other background variables, i.e. due to clinical variability, minor variation in the prevalence of cryptococcal antigenemia is likely to happen in different settings. Further, as most of the participants had CD4 count less than 100 cells/μl, relatively higher proportion of Cryptococcal antigenemia is more likely to be reported among these immunosuppressed HIV patients in these settings \[[@CR42]\]. In contrast to our result, a relatively lower prevalence (2.9%) of Cryptococcal antigenemia among HIV/AIDS patients was reported in United States in 2012 \[[@CR21]\]. Difference in ART adherence and HIV care might contribute for the lower prevalence of the case in the US than most African countries.

With regard to the possible predictors of cryptococcal antigenemia, body mass index\< 18.5 kg/m2, CD4 count \< 100 cells, presented with headache and male gender were reported by two or more articles as an important predictors of cryptococcal antigenemia that could potentially be utilized for public health measures. These all might directly or indirectly contributed for reduced immune status of individuals that could put them at risk for different opportunistic infections, including cryptococcosis. Specifically, lower CD4 count has strong correlation with sever immune depletion, hence risk of opportunistic infections. Liechty et al. (2007) reported that among HIV-infected individuals with CD4 cell count \< 100 cells/μl, cryptococcal antigenemia was associated with a higher risk of death than CrAg negative participants \[[@CR30]\]. Other studies in different settings also reported that lower CD4 count (usually \< 100 cells/mm), low body mass index, having neck pain and signs of meningeal irritation were an important predictors of cryptococcal antigenemia \[[@CR18]--[@CR21], [@CR55]\]. Thomsen et al. (2018) reported that self-reported headache and fever were also predictors of a positive CrAg test \[[@CR59]\].

In our review almost half of the papers reported 10--80.6% proportion of headache and 17.9 and 100% proportion of clinical stage IV HIV disease among HIV patients. Few of other papers reported these variables as an important predictor of cryptococcal antigenemia \[[@CR44], [@CR45], [@CR47], [@CR48]\]. Therefore, stakeholders and policy makers should consider target screening and management of HIV patients coming-up with such kind of associated factors to decrease the morbidity and mortality associated with cryptococcal infection in resource limited settings.

Strength and limitations {#Sec17}
------------------------

This systematic review presented the prevalence of cryptococcal antigenemia and its predictors among HIV patients in resource limited settings, which is an added knowledge on the existing literature \[[@CR55]\]. It includes studies from different settings: Africa, Asia and Latin America that allowed incorporating a better representation of data for policy making.

However, our review should be interpreted in light of a couple of drawbacks including but not limited to the small number of included studies despite the setting covers large number of countries. Especially, Latin America is underrepresented in this review. As a result, the absence of data from some countries might compromise the overall picture of the prevalence of cryptococcal antigenemia and its predictors for clear understanding of the problem for further considerations. The review didn't provide data on the CrAg titer and specific cryptococcal species involved in positive CrAg tests. The other possible pitfall of this review is the variation in demographic characteristic of the study subjects (clinical variability). Finally, the other limit relates to the point in time analysis of studies with cross-sectional study designs, as majority of the articles were this type, which inherently could affect the overall picture of the magnitude of cryptococcal antigenemia. Restricting our inclusion criteria to include only articles published in English languages may have missed relevant studies and reduced the precision of our results.

Conclusions {#Sec18}
===========

The pooled prevalence of cryptococcal antigenemia among HIV infected patients at different CD4 count and ART status was at 8%. Body mass index\< 18.5 kg/m^2^, CD4 count \< 100 cells, presenting with headache and male gender were reported by two or more articles as an important predictors of cryptococcal antigenemia. Therefore, it will be good to consider routine screening for CrAg among HIV infected patients specifically those presenting with these predictors. Policy makers should consider the implementation of targeted screening and treatment interventions for asymptomatic cryptococcal antigenemia patients in resource limited settings. Meningitis associated with cryptococcosis might be a reflection of HIV treatment programme failure; therefore timely HIV testing and rapid linkage to care will have paramount importance for patients. Finally, further work is needed to better define the scope of the problem and track the epidemiology of this infection, in order to prioritize prevention, diagnosis, and treatment strategies.
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**Additional file 1 Supplement 1:** Search Strategy

AIDS

:   Acquired Immunodeficiency Syndrome

ART

:   Anti-Retroviral Therapy (or Treatment)

*C. neoformans*

:   *Cryptococcus neoformans*

CD

:   Cluster of Differentiation

CI

:   Confidence Interval

CM

:   Cryptococcal Meningitis

CNS

:   Central Nervous System

CrAg

:   Cryptococcal Antigen

CSF

:   Cerebrospinal Fluid

EIA

:   Enzyme Immunoassay

HIV

:   Human Immunodeficiency Virus

JBI

:   Joanna Briggs Institute

LFA

:   Lateral Flow Assay

UNAIDS

:   United Nations Programme on HIV/AIDS

WHO

:   World Health Organization
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